Friedreich Ataxia Patient Tissues Exhibit Increased 5-Hydroxymethylcytosine Modification and Decreased CTCF Binding at the FXN Locus

Sahar Al-Mahdawi, Chiranjeevi Sandi, Ricardo Mouro Pinto, Mark A. Pook

1 Ataxia Research Group, Division of Biosciences, School of Health Sciences and Social Care, Brunel University, Uxbridge, Middlesex, United Kingdom, 2 Molecular Neurogenetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, United States of America

Abstract

**Background:** Friedreich ataxia (FRDA) is caused by a homozygous GAA repeat expansion mutation within intron 1 of the FXN gene, which induces epigenetic changes and FXN gene silencing. Bisulfite sequencing studies have identified 5-methylcytosine (5mC) DNA methylation as one of the epigenetic changes that may be involved in this process. However, analysis of samples by bisulfite sequencing is a time-consuming procedure. In addition, it has recently been shown that 5-hydroxymethylcytosine (5hmC) is also present in mammalian DNA, and bisulfite sequencing cannot distinguish between 5hmC and 5mC.

**Methodology/Principal Findings:** We have developed specific MethylScreen restriction enzyme digestion and qPCR-based protocols to more rapidly quantify DNA methylation at four CpG sites in the FXN upstream GAA region. Increased DNA methylation was confirmed at all four CpG sites in both FRDA cerebellum and heart tissues. We have also analysed the DNA methylation status in FRDA cerebellum and heart tissues using an approach that enables distinction between 5mC and 5hmC. Our analysis reveals that the majority of DNA methylation in both FRDA and unaffected tissues actually comprises 5hmC rather than 5mC. We have also identified decreased occupancy of the chromatin insulator protein CTCF (CCCTC-binding factor) at the FXN 5' UTR region in the same FRDA cerebellum tissues.

**Conclusions/Significance:** Increased DNA methylation at the FXN upstream GAA region, primarily 5hmC rather than 5mC, and decreased CTCF occupancy at the FXN 5' UTR are associated with FRDA disease-relevant human tissues. The role of such molecular mechanisms in FRDA pathogenesis has now to be determined.

Introduction

FRDA is an autosomal recessive neurodegenerative mitochondrial disorder caused primarily by a homozygous GAA repeat expansion mutation within intron 1 of the FXN gene [1]. Unaffected individuals have up to 43 GAA repeats, while affected individuals have 44 to 1700 GAA repeats, most commonly between 600–900 GAA repeats [2,3]. The length of the smaller GAA repeat correlates with FRDA disease severity and inversely correlates with the age of onset [4,5]. The effect of the GAA repeat expansion is to decrease expression of the essential and ubiquitously expressed mitochondrial frataxin protein, with levels in FRDA patients ranging from 4% to 29% that of normal [6]. Reduced levels of frataxin in FRDA patients are associated with defects of iron–sulphur (Fe–S) cluster biosynthesis [7], mitochondrial iron accumulation in the heart, spinal cord and dentate nucleus of the cerebellum [8] and increased susceptibility to oxidative stress [9].

Two main hypotheses have been proposed to link FXN GAA repeat expansions with decreased frataxin expression. Firstly, evidence from in vitro and cell transfection studies suggests that GAA repeat expansions may adopt abnormal non-B DNA structures (triplexes or “sticky DNA”) or DNA-RNA hybrid structures (R-loops), which impede the process of RNA polymerase II and thus reduce FXN gene transcription [10,11]. Secondly, there is evidence that GAA repeat expansions can induce heterochromatin-mediated gene silencing effects [12]. Consistent with the latter hypothesis, several FRDA-related
epigenetic changes have been identified in the immediate vicinity of the expanded GAA repeats of the FXN gene [13]. An initial investigation of DNA methylation of the FXN gene by bisulfite sequencing revealed hypermethylation of the cytosine residue of specific CpG sites upstream of the GAA repeat sequence in FRDA patient lymphoblastoid cells compared to cells derived from unaffected individuals [14]. We have subsequently used bisulfite sequencing to identify increased DNA methylation at the upstream GAA repeat region in FRDA patient cerebellum and heart autopsy tissues, which are clinically relevant tissues in FRDA [15]. Interestingly, we also identified reduced levels of DNA methylation in the downstream GAA repeat region in FRDA patient tissues compared with controls. These findings have now been confirmed by bisulfite-based Epityper MassARRAY analysis of blood and buccal cell samples from a large cohort of FRDA patients, where a significant inverse correlation was also detected between the level of DNA methylation in the upstream GAA region and the level of FXN expression [16]. Yet another study has shown that the degree of DNA methylation in the upstream GAA repeat region in FRDA patients correlates with the length of the GAA repeats and inversely correlates with the age of disease onset [17]. Therefore, there is good evidence that DNA methylation may have some role to play in the molecular mechanism of GAA repeat induced FRDA disease. However, bisulfite sequencing is a somewhat time-consuming procedure. Therefore, we now report a more rapid MethylScreen restriction enzyme digestion and qPCR procedure, which we have validated by confirming increased DNA methylation at the upstream GAA repeat region in FRDA patient cerebellum and heart autopsy tissues. Methylation of mammalian DNA primarily occurs as 5mC modification of CpG dinucleotides. However, recent studies have revealed the existence of an alternative modification, 5hmC, which is formed by oxidation of 5mC by ten-eleven translocation (TET) enzymes [18,19]. The overall levels of 5hmC in the mammalian genome are approximately 10% of 5mC levels [20], although higher levels have been detected in tissues of the central nervous system [21]. For example, 5hmC is approximately 40% as abundant as 5mC in the DNA of Purkinje cells of the cerebellum [18]. There are two main theories regarding the function of 5hmC. Firstly, 5hmC may be an intermediate in the removal of 5mC by an active demethylation process that involves the base excision repair pathway [22]. Secondly, 5hmC may be an epigenetic modification in its own right, regulating chromatin or transcriptional factors involved in processes such as neurodevelopment [23]. Therefore, it is possible that 5hmC may also be involved in epigenetic-based disease mechanisms, such as those proposed for FRDA. However, useful information cannot be obtained from previous bisulfite sequence DNA methylation data, because this method does not distinguish between 5mC and 5hmC [24]. Therefore, we have analysed the DNA methylation status of one of the FXN upstream GAA CpG sites in FRDA cerebellum and heart tissues using a procedure that does allow distinction between 5hmC and 5mC and we report that the majority of the methylated DNA at this CpG residue comprises 5hmC rather than 5mC.

In addition, another factor that has been proposed to be involved in silencing of the FXN gene in FRDA is the chromatin insulator protein CTCF, because decreased occupancy of CTCF has been identified at the FXN 5’ UTR region of FRDA fibroblast cells [25]. Therefore, we have decided to further investigate CTCF occupancy in FRDA cerebellum tissue and we report decreased occupancy of CTCF at the FXN 5’ UTR region. Overall we show that increased 5hmC at the FXN upstream GAA region and decreased CTCF occupancy at the FXN 5’ UTR region are both associated with FRDA disease-relevant human tissues.

Materials and Methods

DNA preparation from human tissues

Human cerebellum and heart tissue samples were obtained from autopsies of four FRDA patients (aged 17, 24, 36 and 47, each homozygous for GAA repeat expansions within the range of approximately 550-750 units) and four unaffected individuals (aged 69-82, obtained from NDRI). Research ethical approval was obtained from the SHSSC Research Ethics Committee, Brunel University, and samples were obtained with written consent and were stored in accordance with UK Human Tissue Authority ethical guidelines. For the FRDA patient aged 17, written informed consent was obtained from the next of kin under the organisation of the Friedreich’s Ataxia Group tissue donor scheme. Genomic DNA was isolated from frozen tissues by standard phenol/chloroform extraction and ethanol precipitation.

MethylScreen analysis

Four CpG sites in the FXN upstream GAA repeat region, designated 3, 6, 11 and 13 (numbered according to [14], Figure 1), were investigated using adaptations of the previously described MethylScreen assay [26]. 1µg of genomic DNA was digested with: (1) a methylation-sensitive restriction enzyme (MSRE), (2) a methylation-dependent restriction enzyme (MDRE), (3) both MSRE and MDRE (double digest, DD), and (4) neither MSRE or MDRE (mock control). The MSREs used for CpGs 3, 6, 11 and 13 were AciI (Fermentas), Hpy188III (New England Biolabs), AjiI (Fermentas) and Eco72I (Fermentas), respectively. The MDRE used for all four CpGs was McrBc (Fermentas). A 50ng aliquot of digested DNA was then amplified by quantitative PCR using SYBR® Green (Applied Biosystems) and an ABI7900HT Fast Real-Time PCR System with the following primers: CpG3 F 5’-GAGACCTGCTTTGTTCCTGTG-3’ and R 5’-GTTTCTCCTTCTTCAAGCCGTG-3’; CpG6 F 5’-GAAATGCGCAAGAATTGTTAG-3’ and R 5’-GAGGAAACAAATATGGCTTGG-3’; CpG11 and CpG13 F-metal 5’-GAACGGTTCTGGGAAGGCG-3’ and R-metal 5’-ATCCGAAGTTTCTCTAAACAAATG-3’. PCR quantification was carried out using the ΔΔt method (values were calculated as 2^-ΔΔt (mock - digested) with the mock value set at 100%) and RQ Manager software (Applied Biosystems). Each qPCR reaction for each sample was performed in triplicate in a 96-well plate.
MethylScreen DNA methylation values were then calculated as follows: Densely methylated (DM) = (MSRE-DD)/(100-DD) x 100; unmethylated (UM) = (MDRE-DD)/(100-DD) x 100; intermediately methylated (IM) = 100 - (DM+UM).

5hmC analysis

Levels of 5mC and 5hmC were determined at CpG site 12 (numbered according to [14]) of the FXN upstream GAA repeat region (Figure 1) using the EpiMark™ Analysis Kit (New England Biolabs). 1μg genomic DNA was glucosylated with T4 B-glucosyltransferase (T4-BGT), and then both glucosylated (G) and non-glucosylated (NG) DNA samples were digested with the methylation sensitive restriction enzyme, HpaII, or the methylation insensitive restriction enzyme, Mspl. Digested DNA, together with non-digested (mock control) DNA samples were then amplified by quantitative PCR using SYBR® Green (Applied Biosystems) on an ABI7900HT Fast Real-Time PCR System with F-met and R-met PCR primers (the same as used for MethylScreen analysis). PCR quantification was carried out using the ΔΔCt method and RQ Manager software (Applied Biosystems). Each qPCR reaction for each sample was performed in duplicate in a 96-well plate.

CTCF electrophoretic mobility shift assay (EMSA)

EMSA was performed with recombinant CTCF protein and three γ-32P end-labelled FXN probes, together with CTCF-positive (DM1 (1)) and CTCF-negative (DM1 (3)) probes [27]. The probes were prepared by PCR amplification of human genomic DNA using the following primer pairs: FXN 5’ UTR, F 5’-AAGCAGGCTCTCCATTTTTG-3’, R 5’-CGAGAGTCCACATGCTGCT-3’; FXN GAA Upstream, F 5’-GAACCCAAAAGAATGGCTGTG-3’, R 5’-TTCCCTTCCTGTGAACACC-3’; FXN GAA Downstream, F 5’-TGGTTGTGTCAGCAGGTTG-3’, R 5’-CAGAATTCGCCAAGCTCG-3’. 32P end-labelled labelled PCR products were gel purified using Geneclean III (BIO 101) and end-labelled with γ-32P ATP using T4 polynucleotide kinase. Labelled PCR products were put through a Microspin S-200 HR column (GE HealthCare) and then incubated with 0.2μg of CTCF full-length recombinant protein (Abnova) in PBS buffer containing 5mM MgCl₂, 0.1mM MnSO₄, 1mM DTT, 0.1% Nonidet P-40, 10% glycerol and 1μg of double-strand competitor DNA poly(dI-dC) (Sigma). After incubation for 30 minutes at room temperature, samples were run on a 5% nondenaturing polyacrylamide gel in 0.5X TBE buffer at 100V for 1-2 hours. Gels were then vacuum dried and exposed to ECL Hyperfilm (GE HealthCare), followed by film development.

CTCF chromatin immunoprecipitation (ChIP)

Human cerebellum tissue samples (30mg from each of three FRDA and three unaffected controls, the same as used for DNA preparation) were homogenised, followed by cross-linking of DNA and protein by formaldehyde treatment. Cell nuclei were isolated by centrifugation and then lysed in the presence of protease inhibitors [15]. DNA was sheared by sonication, followed by immunoprecipitation with anti-CTCF antibody (Upstate 07-729). After reversal of cross-linking, qPCR amplification of the resultant co-immunoprecipitated DNA was carried out with SYBR® Green in an ABI7400 sequencer (Applied Biosystems) using FXN 5’ UTR primers and GAPDH (negative for CTCF) control primers as previously described [25]. PCR quantification was carried out using the ΔΔCt method and RQ Manager software (Applied Biosystems). Each value of immunoprecipitated DNA was normalised to both input and GAPDH values. Each tissue sample was subjected to four independent ChIP procedures, followed by triplicate qPCR analysis.

Statistical analysis

Comparison of data from FRDA patients and unaffected control samples was carried out using the student’s t test with a significance value set at P<0.05.

Results

MethylScreen analysis is a rapid method to quantify DNA methylation in the FXN upstream GAA repeat region

We, and others, have previously used bisulfite sequencing to quantify DNA methylation changes at the FXN upstream GAA repeat region in FRDA cells and tissues [14–17]. However, bisulfite sequencing is a somewhat time-consuming procedure, which can be subject to errors due to incomplete bisulfite treatment. Therefore, we have now adapted the previously described MethylScreen assay [26] to rapidly quantify the DNA methylation status at four CpG sites at the FXN upstream GAA repeat region, designated 3, 6, 11 and 13 according to [14] (Figure 1). The MethylScreen method does not require bisulfite treatment of DNA, but involves digestion of genomic DNA with a MSRE, a MDRE, and both a MSRE and a MDRE, followed by qPCR amplification of the residual non-digested DNA using an ampiclon that spans the CpG site of interrogation. The output data is expressed as three levels of DNA methylation status:
unmethylated (UM), intermediately methylated (IM) and densely methylated (DM). We validated the MethylScreen assay by investigating the levels of DNA methylation at CpG11 and CpG 13 in cerebellum and heart tissue from FRDA patients and unaffected controls, which allowed a direct comparison with our previously reported bisulfite sequence analysis [15]. In addition, we investigated CpG3 and CpG6 in cerebellum and heart tissue, since these sites together with CpG13 have previously been identified as the three sites of most significant DNA methylation increase in FRDA versus control lymphoblastoid cells [14]. Our results for cerebellum tissue reveal an increase in DNA methylation at all four CpG sites in FRDA tissue compared with unaffected control tissue, in agreement with all previous bisulfite sequencing data (Figure 2). However, the magnitude of this DNA methylation increase was found to vary from a non-statistically significant small increase in DM of 6% to 20% at CpG3, through an intermediate level of increase in DM of 4% to 68% at CpG6 (P<0.001), to high levels of increase in DM of 14% to 96% at both CpG11 and CpG13 (both P<0.001). The results for heart tissue also reveal significant increases in DNA methylation at all four CpG sites in FRDA tissue compared with unaffected control tissue, with DM values increasing from 0% to 93% at CpG3 (P<0.001), 15% to 92% at CpG6 (P<0.001), 32% to 83% at CpG11 (P<0.01) and 21% to 97% at CpG13 (P<0.001), again in agreement with all previous bisulfite sequencing data (Figure 3). Therefore, the specific MethylScreen protocols that we have developed can be considered as both rapid and robust procedures to investigate DNA methylation status at the FXN locus.

5hmC is the predominant constituent of DNA methylation in the FXN upstream GAA repeat region and is increased in FRDA cerebellum and heart tissues

Levels of 5mC and 5hmC were determined at CpG site 12 of the FXN upstream GAA repeat region (Figure 1) using the EpiMark™ Analysis Kit (New England Biolabs). This CpG site was chosen because it resides within a CCGG motif, which is required by the EpiMark™ procedure for differential restriction enzyme digestion by HpaII and MspI. The principle of this technique depends on the addition of glucose to the hydroxyl group of 5hmC via an enzymatic reaction utilising T4-BGT. Genomic DNA is glucosylated, then digested with a methylation sensitive restriction enzyme, HpaII, and a methylation insensitive restriction enzyme, MspI. If 5hmC is present in the context of CCGG, this modification converts a normally cleavable MspI site to a non-cleavable one.

Initial determination of DNA methylation levels (combined 5mC and 5hmC) by observing HpaII + G and HpaII qPCR values at CpG12 in cerebellum tissue reveals a significant increase in DNA methylation in FRDA tissue compared with unaffected control tissue (Figure 4A), at levels similar to those previously identified by bisulfite sequencing. Thus, DNA methylation levels increase from either 36% to 77% (HpaII + G, P<0.01) or 30% to 87% (HpaII, P<0.05) compared with previously reported bisulfite sequence values of 40% to 95% [15]. However, more detailed analysis reveals that there is no difference in the MspI + G and HpaII + G qPCR results from unaffected cerebellum tissues, and similarly there is no difference in the MspI + G and HpaII + G qPCR results from FRDA cerebellum tissues (Figure 4A). This indicates that all methylated DNA in both the unaffected and the FRDA cerebellum tissue comprises 5hmC rather than 5mC. Therefore, we can now conclude that a characteristic feature of FRDA cerebellum tissue is an increase in 5hmC-modified DNA
in the FXN upstream GAA repeat region, at least at CpG site 12. Determination of DNA methylation levels (combined 5mC and 5hmC) in heart tissue also reveals a significant increase in DNA methylation in FRDA tissue compared with unaffected control tissue (Figure 4B), at levels similar to those previously identified by bisulfite sequencing. Thus, DNA methylation levels increase from either 44% to 100% (HpaII + G, \( P<0.01 \)) or 37% to 89% (HpaII, \( P<0.001 \)) compared with previously reported bisulfite sequence values of 65% to 95% [15]. However, more detailed analysis of the MspI + G compared with HpaII + G qPCR results indicates that the methylated DNA comprises approximately 64% 5hmC in the unaffected heart tissues and only 37% 5hmC in the FRDA heart tissues, although there is still an overall increase in 5mC levels (MspI + G values) in FRDA compared with controls (Figure 4B). This suggests that, while there is increased DNA methylation in both cerebellum and heart tissues, there are also tissue specific differences: DNA methylation is entirely due to 5mC in the cerebellum, but only partially due to 5mC in the heart.

CTCF occupancy at the FXN 5’ UTR region is decreased in FRDA cerebellum tissue

We firstly performed in silico screening of a 40kb region spanning the FXN gene for potential CTCF binding sites using the bioinformatics web tool designed by Klenova and colleagues ([http://www.essex.ac.uk/bs/molonc/spa.htm](http://www.essex.ac.uk/bs/molonc/spa.htm)) and we identified three regions of interest at the start of the FXN gene. We then investigated the three potential CTCF binding regions, which were located within the 5’ UTR, GAA upstream and GAA downstream regions of the FXN locus (Fig 1), by EMSA using recombinant full length CTCF protein. Only the 5’ UTR probe proved capable of binding CTCF protein to cause a gel shift (Figure 5A). This result is in agreement with a previous report that identified CTCF binding in the FXN 5’ UTR region using fibroblast cell lysates [25]. We then performed ChIP analysis to assess the level of CTCF binding at the 5’ UTR site in three FRDA cerebellum tissue lysates compared with three unaffected controls, using the same qPCR amplicons as previously described [25]. A statistically significant decrease (\( P<0.05 \)) in CTCF binding was detected in FRDA cerebellum, with levels falling to only 20% of the levels detected in unaffected cerebellum controls (Figure 5B).

Discussion

We have investigated two molecular mechanisms that may be involved in the disease process in FRDA patient cerebellum and heart tissues. Firstly, we have developed a rapid and robust MethylScreen method to determine the general DNA methylation status (5mC and 5hmC) at the FXN upstream GAA repeat region. The level of DNA methylation in FRDA cerebellum tissue showed a gradation across the four CpG sites investigated, progressively increasing as you move closer to the GAA repeat locus. This suggests that the GAA repeat expansion mutation may act as focal point to induce only a localised effect of DNA methylation, spreading upstream from this point. However, this gradation effect was not seen in FRDA heart tissue, which demonstrated high levels of DNA methylation at all 4 CpG sites, indicating a degree of variability in the DNA methylation process in different FRDA tissues. Such variability may have some bearing on the previously identified differences in GAA repeat somatic instability, with cerebellum showing high levels of instability, while heart is comparatively stable [28].

Subsequently, we have shown that the methylated DNA at one CpG site in the FXN upstream GAA repeat region comprises entirely 5hmC in FRDA cerebellum, but only partially 5hmC in FRDA heart. Our results are in agreement with the recent report that 5hmC is particularly associated with human cerebellum throughout development [29]. However, we can discount the possibility that the increased 5mC that we have observed in FRDA tissues is a non-specific age-related effect in neuronal tissues, as previously reported for mouse hippocampus and cerebellum [23,30], because our FRDA patients are actually younger than the unaffected controls.
Further studies will be required to determine if our finding is a general increased 5hmC effect for CpG sites within the FXN upstream GAA region, or indeed within other regions of the genome. The high levels of 5hmC that we have detected at the FXN upstream GAA region could be explained by either a passive or an active process. Thus, 5hmC could merely be a non-functioning intermediate in a demethylation process that is attempting to reverse the GAA repeat expansion-induced 5mC DNA methylation that is associated with FXN gene silencing [17]. In this case, the differences that we have detected between 5hmC levels in cerebellum and heart tissues could perhaps be due to tissue-selective differences in the efficiency of the TET enzymes that convert 5mC to 5hmC [18,19] or the DNA repair systems (e.g. base excision repair) that are required to convert 5hmC to cytosine [22]. Alternatively, 5hmC may have an as yet unidentified role in regulation of gene expression. For example, it has shown in vitro that 5hmC at the promotor but not in the gene body negatively regulates gene expression [31]. Furthermore, it has been proposed that 5hmC may be involved in the regulation of genes that are silent but transcriptionally poised for activation, where there is loss of 5mC, recruitment of Polycomb repressive complex 2 (PRC2) and, therefore, methylation of histone 3 at lysine 27 (H3K27me3) [20]. Indeed, 5hmC and H3K27me3 have been shown to have high correlation across a variety of somatic tissues [32]. Therefore, it is interesting to note that the FXN gene demonstrates RNA polymerase II pausing and FRDA lymphoblastoid cells have shown increased levels of H3K27me3 in the FXN upstream GAA repeat region [33,34]. In addition, it has been proposed that 5hmC may inhibit DNMT1 binding and may therefore function as a negative regulator of 5mC levels at protein-DNA interaction sites, allowing the binding of enhancer proteins or transcription factors [35]. Furthermore, 5hmC has been reported to bind MECP2, particularly in the CNS, although the functional consequences of such an interaction are not yet known [36]. Although the close positioning of the GAA repeat expansion mutation and the increased 5hmC modification of DNA in the FXN upstream GAA repeat region in FRDA would suggest a likely causal relationship, there may also be other more general factors involved in the formation of 5hmC. For example, the TET enzymes that produce 5hmC are known to be dependent on Fe(II) and α-ketoglutarate. Therefore, disruptions of iron metabolism, oxidative stress and the TCA cycle, processes which are highly relevant to FRDA, may all potentially affect 5hmC levels [37].

The second molecular change that we have identified in FRDA cerebellum is reduced CTCF occupancy at the FXN 5’ UTR region, confirming previous findings in FRDA fibroblast cells [25]. It has been hypothesized that decreased binding of CTCF in FRDA cells may be an epigenetic switch that allows increased frataxin antisense (FAST-1) transcription, spread of heterochromatin and resultant FXN gene silencing. DNA methylation has not been thought to play an active role in this process, because increased DNA methylation has not been detected at the CTCF binding site in the FXN 5’ UTR region of FRDA cells or tissues [15,16,25], and the increased DNA methylation at the FXN upstream GAA repeat region has been considered to be an unconnected marker of the heterochromatin state. However, if there is a demethylation process occurring at the FXN upstream GAA repeat region, as indicated by the high levels of 5hmC that we have now identified, then this may indeed be involved in increasing FAST-1 expression, CTCF depletion and hence FXN gene silencing. In conclusion, we can propose a model for FRDA that combines both the increased 5hmC modification of DNA and decreased CTCF binding at the FXN locus. Further studies will now be required to determine the exact relationship between these molecular mechanisms and FRDA pathogenesis.
Acknowledgements

The unaffected human tissues used in this study were provided by the National Disease Research Interchange (NDRI).

Author Contributions

Conceived and designed the experiments: SA RMP MAP. Performed the experiments: SA CS RMP MAP. Analyzed the data: SA CS RMP MAP. Wrote the manuscript: SA CS RMP MAP.

References

1. Campuzano V, Montermini L, Moltó MD, Pianese L, Cossè M et al. (1996) Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271: 1423-1427. doi: 10.1126/science.271.5254.1423. PubMed: 8596916.

2. Pandoño M (2009) Friedreich ataxia: the clinical picture. J Neurol 256 Suppl 1: 3-8. doi: 10.1007/s00415-009-0097-x. PubMed: 19283346.

3. Sharma R, De Biase I, Gómez M, Delatycki MB, Ashizawa T et al. (2004) Friedreich ataxia in carriers of unstable borderline GAA triplet-repeat alleles. Ann Neurol 56: 898-901. doi: 10.1002/ana.20333. PubMed: 15562408.

4. Dürr A, Cossee M, Agid Y, Campuzano V, Mignard C et al. (1996) Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med 335: 1116-1175. doi: 10.1056/NEJM199610313351601. PubMed: 8815938.

5. Filla A, De Michele G, Cavalcanti F, Pianese L, Monticelli A et al. (1996) The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet 59: 554-560. PubMed: 8751856.

6. Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C et al. (1997) Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 6: 1771-1780. doi: 10.1093/hmg/6.11.1771. PubMed: 9302253.

7. Bradley JL, Blake JC, Chamberlain S, Thomas KP, Cooper JM et al. (2000) Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum Mol Genet 9: 275-282. doi: 10.1093/hmg/9.3.275. PubMed: 10607838.

8. Koeppen AH, Michael SC, Knutson MD, Haile DJ, Qian J et al. (2007) The dentate nucleus in Friedreich’s ataxia: the role of iron-responsive proteins. Acta Neuropathol 114: 163-173. doi:10.1007/s00401-007-0220-y. PubMed: 17443334.

9. Wong A, Yang J, Cavadin P, Gellera C, Lonnerdal B et al. (1999) The Friedreich ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol Genet 8: 425-430. doi: 10.1093/hmg/8.4.425. PubMed: 9949201.

10. Grabczyk E, Mancuso M, Sammarco MC (2007) A persistent RNA.DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro. Nucleic Acids Res 35: 1625-1634. doi:10.1093/nar/gkm271. PubMed: 17478498.

11. Castaldo I, Pinelli M, Monticelli A, Acquaviva F, Giacchetti M et al. (2008) DNA methylation in intron 1 of the frataxin gene is related to the GAA repeat length and age of onset in Friedreich’s ataxia patients. Ann Neurol 61: 55-60. doi: 10.1002/ana.20333. PubMed: 18211957.

12. Castaldo I, Pinelli M, Monticelli A, Acquaviva F, Giacchetti M et al. (2007) The presence of 5-methylcytosine in Purkinje neurons and the brain. Hum Mol Genet 16: 4299-4309. doi: 10.1093/hmg/ddm239. PubMed: 17619157.

13. Branco MR, Ficz G, Reik W (2011) Uncovering the role of 5-hydroxymethylcytosine in the epigenome. Nat Rev Genet 13: 7-13. doi: 10.1038/nrg.3192. PubMed: 22083101.

14. Gloecksh B, Münzel M, Müller M, Michalakis H, Wagner M et al. (2010) Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLOS ONE 5: e13536. doi: 10.1371/journal.pone.0013536. PubMed: 21203455.

15. Guo J, Ly X, Gong G, Song H (2011) Hydroxilation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 145: 423-434. doi:10.1016/j.cell.2011.03.022. PubMed: 21496894.

16. Szulwach KE, Li X, Li Y, Song CX, Wu H et al. (2011) 5-hmc-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci 14: 1607-1616. doi:10.1038/nn.2955. PubMed: 22037496.

17. Huang Y, Pastor WA, Shen Y, Tahiliani M, Liu DR et al. (2010) The behaviour of 5-hydroxymethylcytosine in bisulfitte sequencing. PLOS ONE 5: e8888. doi: 10.1371/journal.pone.0008888. PubMed: 20128651.

18. Al-Mahdawi S, Monticelli A et al. (2007) Progressive GAA expansions in dorsal root ganglia of Friedreich’s ataxia patients. Ann Neurol 61: 55-60. doi:10.1002/ana.21052. PubMed: 17262846.

19. Wang T, Pan Q, Lin L, Szulwach KE, Song CX et al. (2012) Genomic-wide DNA hydroxymethylation changes are associated with neurodevelopmental genes in the developing human cerebellum. Hum Mol Genet 21: 5500-5510. doi:10.1093/hmg/dda394. PubMed: 23042784.

20. Chen H, Dzitoyeva S, Manev H (2012) Effect of aging on 5-hydroxymethylcytosine in the mouse hippocampus. Restor Neurosci 30: 237-245. PubMed: 22426040.

21. Sherry ST, Ward MH, Kholodov M, Baker TS, Phan L et al. (2001) dbSNP: the NCBI database for single nucleotide polymorphisms. Nucleic Acids Res 29: 308-311. PubMed: 11084126.

22. Hubacek JA, Zimin AI, Green PL et al. (2014) The International Phasing and Mapping of the Human Genome. Nature 508: 321-327. doi: 10.1038/nature13282. PubMed: 25042752.

23. Stadler T, Sherry ST, Ward MH et al. (2013) dbSNP137: the 2013 update includes 14.8 million non-ancestral alleles from 210,164 genomes. Nucleic Acids Res 41: D981-D989. doi: 10.1093/nar/gks1170. PubMed: 23172426.

24. Storch H, Feng S, Morey Kinney S, Pradhan S, Jacobsen SE (2011) 5-Hydroxymethylcytosine is associated with enhancers and gene bodies
36. Mellén M, Ayata P, Dewell S, Kriaucionis S, Heintz N (2012) MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell 151: 1417-1430. doi: 10.1016/j.cell.2012.11.022. PubMed: 23260135.

37. Chia N, Wang L, Lu X, Senut MC, Brenner C et al. (2011) Hypothesis: environmental regulation of 5-hydroxymethylcytosine by oxidative stress. Epigenetics 6: 853-856. doi:10.4161/epi.6.7.16461. PubMed: 21617369.